配伍配比是方剂的核心与灵魂所在，是中医药的特色和优势，它既不是简单的药物作用在数量上的相加，也不是机械的毒副反应的抵消，而是在辨证立法基础上，以法统方，立方遣药，有序组合而成的有制之师。本研究以复方丹参方中的丹参、三七为对象，采用整体动物模型和离体细胞模型，对二者的配伍配比进行了优选研究，并利用数学方法对实验所得生物信息进行综合评价，得到适宜配比，为中成药的二次开发建立了一种新模式。

Background: Traditional Chinese medicine (TCM), especially herbal medicine, has been widely used in China and now is also being incresingly used in other countries for the treatment of cardiovascular diseases. Although many studies have demonstrated that certain Chinese herbal products are effective and safe for the treatment of cardiovascular diseases, most of these lack sufficient quality. Therefore, large randomized clinical trials and further scientific research to determine ist safety, effectiveness are necessary QiShen YiQi Dripping Pills (QSYQDP) is a herbal preparation clinically used in the treatment and prevention of coronary artery disease. Preliminary observations have shown its safety and effectiveness. Methods/Design: This randomized, controlled trial will recruit 3600 patients with a history of myocardial infarction. Patients will be randomized into two groups by a Centr-Randomized System. One group receivcs QSYQDP, the other group receive aspirin. This trial protocol will describe eligibility criteria, detailed information on the treatment definition, blinding, endpoints, statistical methods, sample size ditermination, data management, legal aspects, and the current status of the trial. Discussion: This trial is one of the first randomized, controlled clinical trial to evaluate the results of this study should help to difine the role of TCM in modern medical care, as well as to provide the management strategy for CAD patients in China and other countries. (J Geriatr Cardiol 2006; 3 (2): 116-9.)

证候是中医理论的核心内容，也是中医认识生命活动的科学理论和方法。在中药新药研发中，证候疗效评价一直是具有中医特色的热门研究领域。本文从证候研究重要性、证候确立依据和构成、证候诊断标准、证候计量方法、证候疗效评价方法及关键点五个方面加以阐述，认为在注意吸收国际上药物评价的新观念、新方法的同时，更要重视能反映中医诊疗优势和特色的评价方法和指标。

目的：观察丹参、三七不同配比对实验性犬急性心肌缺血的影响。方法：采用冠脉左前降支结扎法造成急性心肌缺血模型。结果：以丹参为主的四个药对比例组，即10/6、10/3、10/1、10/0，有明显改善犬心肌缺血的作用，减轻由心外膜心电图所标测的心肌缺血程度，减少通过TTC染色所显示的缺血区。其中尤以10/6、10/3两组作用突出。结论：①在主效应范围内，丹参、三七配伍后药效作用要强于单味药物，且配伍存在最佳比例阈；②丹参在直接对抗上要强于三七，三七的优势药效可能在其他靶点上；③同一配伍的不同配比与效应的关系是非线性的。

结合药效物质、体内体外药理实验研究的具体数据进行综合分析，总结出丹参、三七配伍组合后的效应特点和表现形式，进而提出基于组分效应关系、组分配伍优化设计、研制现代中药的新思路。